An open-label study in healthy subjects and in patients with stable impaired renal function to assess the effect of severe renal impairment on licarbazepine pharmacokinetics and metabolism after the single administration of a 500 mg licarbazepine immediate release (IR) tablet

Trial Profile

An open-label study in healthy subjects and in patients with stable impaired renal function to assess the effect of severe renal impairment on licarbazepine pharmacokinetics and metabolism after the single administration of a 500 mg licarbazepine immediate release (IR) tablet

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2007

At a glance

  • Drugs Licarbazepine (Primary)
  • Indications Bipolar disorders
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 17 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top